IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brignole, F.
Right arrow Articles by Baudouin, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brignole, F.
Right arrow Articles by Baudouin, C.
(Investigative Ophthalmology and Visual Science. 2001;42:90-95.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Flow Cytometric Analysis of Inflammatory Markers in KCS: 6-Month Treatment with Topical Cyclosporin A

Françoise Brignole1, Pierre-Jean Pisella2, Magda De Saint Jean2, Marie Goldschild2, Alain Goguel1 and Christophe Baudouin1

1 From the Laboratory of Immunohematology and the 2 Department of Ophthalmology, Ambroise Paré Hospital, APHP, University of Paris-V René Descartes, Boulogne, France.

PURPOSE. Immune-based inflammation has been observed as a common mechanism of keratoconjunctivitis sicca (KCS). In KCS-affected eyes, upregulated expression of HLA DR and various immune- or apoptosis-related markers by conjunctival epithelial cells has been demonstrated in an earlier study, by a technique of flow cytometry in impression cytology (IC) specimens. The purpose of this study was to monitor the effects of topical cyclosporin A on the expression of these markers throughout a 6-month period of treatment.

METHODS. Patients with moderate to severe KCS included in a large European multicenter clinical trial (Cyclosporin Dry Eye Study, Allergan, Irvine, CA) underwent collection of IC specimens at baseline, month 3, and month 6. For 6 months, they randomly received 0.05% or 0.1% cyclosporin A or vehicle. Specimens were processed and analyzed in a masked manner by flow cytometry, using monoclonal antibodies directed to HLA DR, CD40, CD40 ligand, Fas, and the apoptotic marker APO2.7. Percentages of positive cells were calculated and levels of expression quantified after conversion into standardized units of fluorescence.

RESULTS. One hundred fifty-eight patients had at least two IC specimens available for flow cytometry analysis. HLA DR expression, both in percentage of positive cells and level of expression, was highly significantly reduced after 0.05% and 0.1% cyclosporin A treatment at months 3 and 6 compared with baseline values, whereas vehicle did not induce any change in HLA DR expression over time. The 0.05% and 0.1% cyclosporin emulsions were significantly more effective than the vehicle in reducing HLA DR at months 3 and 6 (0.05%), and at month 6 (0.1%). CD40 expression was significantly reduced at month 3 and partially at month 6, compared with baseline, with no reduction in patients who received the vehicle. CD40 ligand expression also decreased at months 3 and 6 in patients taking both concentrations of cyclosporin A. APO2.7 expression was significantly increased in all three groups, whereas percentage of Fas-positive cells decreased only in patients treated with 0.05% cyclosporin A at months 3 and 6.

CONCLUSIONS. Flow cytometry provided an objective technique to monitor the effects of topical cyclosporin A on immune- and apoptosis-related markers in the conjunctival epithelium of patients with KCS enrolled in a large multicenter trial. Topical cyclosporin A strikingly reduced HLA DR and to a lesser extent, other inflammatory and apoptotic markers, whereas the vehicle, used as a control tear substitute, had almost no effect. This study confirms that cyclosporin A may be efficient in reducing conjunctival inflammation in moderate to severe KCS and is consistent with clinical results in this indication.




This article has been cited by other articles:


Home page
IOVSHome page
T. Said, M. Dutot, R. Christon, J.-L. Beaudeux, C. Martin, J.-M. Warnet, and P. Rat
Benefits and Side Effects of Different Vegetable Oil Vectors on Apoptosis, Oxidative Stress, and P2X7 Cell Death Receptor Activation
Invest. Ophthalmol. Vis. Sci., November 1, 2007; 48(11): 5000 - 5006.
[Abstract] [Full Text] [PDF]


Home page
Br J OphthalmolHome page
J.-J. Gicquel, R. Navarre, M. E. Langman, A. Coulon, S. Balayre, S. Milin, M. Mercie, A. Rossignol, A. Barra, P.-M. Levillain, et al.
The use of impression cytology in the follow-up of severe ocular burns
Br J Ophthalmol, September 1, 2007; 91(9): 1160 - 1164.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
B M Lodde, B J Baum, P P Tak, and G Illei
Experience with experimental biological treatment and local gene therapy in Sjogren's syndrome: implications for exocrine pathogenesis and treatment
Ann Rheum Dis, November 1, 2006; 65(11): 1406 - 1413.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
M. Krzyzowska, M. Polanczyk, M. Bas, J. Cymerys, A. Schollenberger, F. Chiodi, and M. Niemialtowski
Mousepox conjunctivitis: the role of Fas/FasL-mediated apoptosis of epithelial cells in virus dissemination
J. Gen. Virol., July 1, 2005; 86(7): 2007 - 2018.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
S. Yeh, X. J. Song, W. Farley, D.-Q. Li, M. E. Stern, and S. C. Pflugfelder
Apoptosis of Ocular Surface Cells in Experimentally Induced Dry Eye
Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 124 - 129.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Association for Research in Vision and Ophthalmology